SUVEN · Suven Life Sciences Ltd · Biotechnology & Drugs
SUVEN · Suven Life Sciences Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
34.3% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹4 Cr
Revenue YoY
PAT YoY
-147.7%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
15.8
P/S (TTM)
1,139.9
Sector P/E
42
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| SUVEN (this stock) | Not meaningful (earnings negative over the last 12 months) | 15.8 | -3995.9% | -59.6% | 0.03 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
falling 2q
FII
falling 2q
MF
0.01% (0.00pp)
stable
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedSuven Life Sciences Limited (SUVEN) reported a consolidated net loss of ₹105.14 crore in FY2023-24, down from ₹118.08 crore in FY2022-23, despite revenue growth to ₹32.82 crore from ₹21.99 crore. The company maintains a strong cash balance of ₹239.87 crore as of March 31, 2024, sufficient to fund research for two years. SUVEN focuses on CNS disorders with five molecules in clinical development, emphasizing R&D as its core. The company has no material defaults, regulatory penalties, or legal disputes, and its internal controls are deemed effective. The auditor noted no material weaknesses in internal controls, and the company has no significant contingent liabilities or disputes.
- Consolidated net loss of ₹105.14 crore in FY2023-24, down from ₹118.08 crore in FY2022-23.
- Revenue increased to ₹32.82 crore in FY2023-24 from ₹21.99 crore in FY2022-23.
- Cash balance of ₹239.87 crore as of March 31, 2024, sufficient for two years of R&D.
- Five molecules in clinical development targeting CNS disorders.
- No material defaults, regulatory penalties, or legal disputes noted.
Key takeaway: Suven Life Sciences continues to incur losses due to high R&D costs but maintains a strong cash position and no significant legal or regulatory issues, with a focus on CNS disorder drug development.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceEarlier (1-3 years ago)
The auditor identified the evaluation of the going concern assumption as a key audit matter due to the company's continuous losses over five years and reliance on external funding, indicating a potential audit qualification or reservation.
Regulatory Action
1 occurrenceRecent (last 12 months)
The company paid a penalty of ₹4.24 lakhs to BSE and NSE for non-compliance under Regulation 19 of SEBI (LODR) Regulations, 2015. The BSE has waived the penalty, but NSE's waiver decision is pending.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
The company has contingent liabilities related to claims arising from disputes not acknowledged as debts -Direct taxes.
Earlier (1-3 years ago)
The company has contingent liabilities related to claims arising from disputes not acknowledged as debts, specifically concerning direct and indirect taxes as of 31 March 2025 and 31 March 2024.
The company has a contingent liability related to claims arising from disputes not acknowledged as debts - Indirect taxes as of 31st March 2024 and 2023.
Related-Party Transaction
1 occurrenceRecent (last 12 months)
The company is seeking approval for the appointment of Dr. Madhavi Jasti, daughter of the Chairman & Managing Director and a Whole-time Director, to an office or place of profit in overseas wholly owned subsidiaries.
Statutory dues in dispute
2 occurrencesRecent (last 12 months)
SUVEN LIFE SCIENCES LIMITED has not deposited statutory dues under the Income Tax Act, 1961 for the assessment years 2018-19, 2019-20, and 2020-21, with disputes pending before the Commissioner (Appeals). The amounts are not specified in the excerpt.
Earlier (1-3 years ago)
The company has disputes pending with the Income Tax Department for the assessment years 2018-19, 2019-20, and 2020-21, related to TDS and income tax penalty, with amounts not yet deposited as of March 31, 2025.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
3.53% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).